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Abstract
Aims/hypothesis To assess thiamine status by analysis of
plasma, erythrocytes and urine in type 1 and type 2 diabetic
patients and links to markers of vascular dysfunction.
Methods Diabetic patients (26 type 1 and 48 type 2) with
and without microalbuminuria and 20 normal healthy
control volunteers were recruited. Erythrocyte activity of
transketolase, the concentrations of thiamine and related
phosphorylated metabolites in plasma, erythrocytes and
urine, and markers of metabolic control and vascular
dysfunction were determined.
Results Plasma thiamine concentration was decreased 76%
in type 1 diabetic patients and 75% in type 2 diabetic
patients: normal volunteers 64.1 (95% CI 58.5–69.7) nmol/l,
type 1 diabetes 15.3 (95% CI 11.5–19.1) nmol/l, p<
0.001, and type 2 diabetes 16.3 (95% CI 13.0–9.6) nmol/l,
p<0.001. Renal clearance of thiamine was increased 24-
fold in type 1 diabetic patients and 16-fold in type 2
diabetic patients. Plasma thiamine concentration correlated
negatively with renal clearance of thiamine (r=−0.531, p<
0.001) and fractional excretion of thiamine (r=−0.616, p<
0.001). Erythrocyte transketolase activity correlated nega-
tively with urinary albumin excretion (r=−0.232, p<0.05).
Thiamine transporter protein contents of erythrocyte mem-
branes of type 1 and type 2 diabetic patients were increased.
Plasma thiamine concentration and urinary excretion of
thiamine correlated negatively with soluble vascular adhe-
sion molecule-1 (r=−0.246, p<0.05, and −0.311, p<0.01,
respectively).
Conclusions/interpretation Low plasma thiamine concen-
tration is prevalent in patients with type 1 and type 2
diabetes, associated with increased thiamine clearance. The
conventional assessment of thiamine status was masked by
increased thiamine transporter content of erythrocytes.
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Abbreviations
ARB angiotensin receptor blocker
ClThiamine renal clearance of thiamine
FEThiamine fractional excretion of thiamine
MNL mononuclear leucocyte
RFC-1 reduced folate carrier-1
sVCAM-1 soluble vascular adhesion molecule-1
THTR-1 thiamine transporter-1
THTR-2 thiamine transporter-2
TK transketolase
TMP thiamine monophosphate
TPP thiamine pyrophosphate
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Introduction
Diabetes is increasing in incidence in the UK and elsewhere
to epidemic proportions. The major health concerns of
diabetes are achieving good control of blood glucose, BP
and lipids to suppress the development of associated
vascular complications—microvascular complications (ne-
phropathy, retinopathy and peripheral neuropathy) and
macrovascular complications (cardiovascular disease and
stroke) [1, 2]. This is not always achievable because of
limitations of current drug therapy, patient compliance and
other factors linked to the development of vascular
complications [3]. Secondarily to the global epidemic of
diabetes, therefore, is a global burden of vascular compli-
cations [4]. The significant residual risk of development of
microvascular and macrovascular complications in prospec-
tive clinical trials where best efforts have been made to
optimise glycaemic control [5, 6], and the failure of major
genetic susceptibility factors for diabetic complications to
emerge from intensive studies [7] (although some may be
found with further study [8, 9]), encourage the search for
other metabolic and nutritional factors that may predispose
to the development of vascular complications in diabetes.
Vascular complications develop progressively from 5–
40 years after the onset of diabetes, although they may appear
earlier in type 2 diabetes when associated with a period of
undiagnosed diabetes and impaired glucose tolerance. A
strategy to counter multiple pathways of biochemical
dysfunction linked to the development of vascular complica-
tions emerged from recent advances in understanding of the
cell biology of diabetic complications: high-dose therapy
with thiamine and related derivatives such as benfotiamine.
High-dose thiamine therapy prevented the development of
microvascular complications in experimental diabetes with-
out improvement of metabolic control, as reviewed in [10].
Experimental diabetes was also associated with tissue-
specific thiamine deficiency characterised by a marked
decrease of plasma thiamine concentration and decreased
activity of the thiamine-dependent enzyme of transketolase
(TK) and decreased levels of TK protein in renal glomeruli
linked to a profound increase in renal clearance of thiamine
(ClThiamine) [11]. Thiamine deficiency was not detected by
the conventional indicator of thiamine status, the erythrocyte
‘thiamine effect’ (the percentage unsaturation of TK with
thiamine pyrophosphate [TPP] cofactor) [12]. The preva-
lence of similar low plasma thiamine concentrations and
impaired renal handling of thiamine in clinical diabetes has
not been addressed previously.
In this study, we sought to establish whether there is a
disturbance of thiamine homeostasis prevalent in type 1 and
type 2 diabetic patients in the UK and if this is linked to
incipient nephropathy and markers of vascular dysfunction
and early stage renal dysfunction.
Methods
Patients and normal healthy volunteers Diabetic patients
were recruited from patients attending the Diabetes Clinic at
Colchester General Hospital, and normal healthy control
volunteers from partners and friends of the patients and
investigators. Inclusion criteria were: diabetic patients with
normoalbuminuria (AER <30mg/24 h) and microalbuminuria
(AER 30–300 mg/24 h); matched for age and sex (18–
65 years); diabetes duration of ≥5 years; HbA1c <10%; and
BMI 19–40 kg/m2. Exclusion criteria were: patients with
end-stage renal disease; severe excess alcohol consumption
(>50 U per week; 1 U is 8 g alcohol); significant comor-
bidities; known allergy or intolerance to thiamine; use of
thiamine supplements or goldenseal (Hydrastis canadensis, a
multipurpose herbal remedy); participating in an intervention
study within 30 days; recipients of renal and/or pancreatic
transplants; and women who were pregnant or breastfeeding
or of child-bearing potential not using adequate contracep-
tive precautions. Twenty-four hour urine collections and
blood samples (fasting) were taken with informed consent of
the patients and volunteers. Plasma, erythrocyte and mono-
nuclear leucocyte (MNL) fractions were prepared immedi-
ately and stored at −80°C until analysis. Ethical approval for
the study was given by the local ethics committee (North and
Mid-Essex Local Research Ethics Committee).
Assay of thiamine and phosphorylated metabolites Thi-
amine status was assessed by measurement of thiamine,
thiamine monophosphate (TMP) and TPP, determined by
HPLC with fluorimetric detection (pre-column derivatisa-
tion to thiachromes) [13]. The retention times, limits of
detection, interbatch CV values and recoveries for these
metabolites were: thiamine 13.1 min, 36 fmol, 1.1 and
97%; TMP 6.0 min, 52 fmol, 2.1 and 92%; and TPP
4.5 min, 51 fmol, 2.9 and 94%. There was no interference
from glucose in the assay and validations were not
significantly different in analysis of samples from normal
healthy volunteers and diabetic patients. Sample storage
studies indicated that analyte content was stable for plasma,
erythrocytes and urine stored at −80°C for at least 6 weeks
and storage of plasma, erythrocyte haemolysate and urine
and related de-proteinised extracts for 8 h. Stock solutions
of thiamine, TMP and TPP were calibrated by spectropho-
tometry assuming molar extinction coefficients of ɛ233=
14.2, ɛ247=15.3 and ɛ247=13.0 (mmol/l)
−1 cm−1, respec-
tively [14]. Shewhart analysis assessing the stability of
analyte estimates in samples every day over a period of ten
consecutive days indicated the analysis had acceptable
quality control (all estimates within mean±2 SD) [15]. The
concentration of thiamine metabolites was determined in
plasma, erythrocytes and urine; ClThiamine and fractional
excretion of thiamine (FEThiamine) were deduced.
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Other biochemical measurements Erythrocyte TK activity
and percentage unsaturation with TPP (thiamine effect)
were determined. Erythrocyte membrane content of thia-
mine transporter-1 (THTR-1) [16] and reduced folate
carrier-1 (RFC-1), a transporter of TMP [17], were
determined by SDS-PAGE electrophoresis and western
blotting, normalising band intensities to β-actin and
preparing erythrocyte membrane protein extracts using the
optimised procedure described in [18], and commercial
antibodies to THTR-1 and RFC-1 (Alpha Diagnostics, San
Antonio, CA, USA).
Markers of metabolic control were determined: plasma
glucose, HbA1c, total cholesterol, HDL-cholesterol, triacyl-
glycerol, systolic and diastolic BP and GFR assessed by
Cockcroft–Gault-corrected creatinine clearance. Markers of
vascular and metabolic dysfunction (plasma plasminogen
activator inhibitor-1; von Willebrand factor and soluble
vascular adhesion molecule-1 [sVCAM-1]; and MNL
protein kinase C) were determined by commercial ELISAs
(Technoclone, Dorking, UK; R&D Systems, Abingdon,
UK; and Stressgen, Ann Arbor, MI, USA, respectively).
Statistical analysis The significance of differences between
mean and median analyte concentrations was determined
using Student’s t test and the Mann–Whitney U test,
respectively, and correlation analysis was performed by
calculating Spearman’s ρ statistic, as indicated in the text.
Data presented are mean±SD or median (minimum–
maximum).
Results
Patient characteristics The characteristics of type 1 and
type 2 diabetic patients and normal healthy control
volunteers recruited for this study are given in Table 1.
The diabetic patients had moderate glycaemic control;
mean HbA1c was 8.6–8.7%. GFR was within the normal
range, indicative of normal renal function for creatinine
clearance. Fifty diabetic patients (17 type 1 and 33 type 2)
had urinary albumin excretion within the normal range
(median 11.5, 2.3–29.1 mg/24 h) and 24 had urinary
albumin excretion characteristic of microalbuminuria and
incipient nephropathy (median 46.1, 30.6–297.3 mg/24 h).
Diabetic patients with and without microalbuminuria were
of similar age (60±14 vs 56±15 years), duration of diabetes
(17±11 vs 16±12 years) and HbA1c (8.9±1.9 vs 8.5±
1.5%). Nine type 1 diabetic patients and 33 type 2 diabetic
patients were receiving therapy with ACE inhibitors or
angiotensin receptor blockers (ARBs).
Thiamine status of patients with type 1 and type 2
diabetes Surveying the thiamine status in the study patients
and normal volunteer groups, we found the plasma
concentration of thiamine was decreased 76% and 75% in
type 1 and type 2 diabetic patients, respectively. The plasma
concentration of thiamine (mean±SD) was: normal volun-
teers 64.1±12.0 nmol/l, type 1 diabetes 15.3±9.6 nmol/l
and type 2 diabetes 16.3±11.5 nmol/l, p<0.001 (Student’s
t test) (Fig. 1a). There was no significant difference
between plasma thiamine concentration of type 1 and type
2 diabetic patients or between diabetic patients with and
without microalbuminuria (14.4±8.9 vs 16.7±11.6 nmol/l,
p>0.05). The urinary excretion of thiamine was increased
fourfold and threefold in type 1 and type 2 diabetic patients
with respect to normal volunteers. The urinary excretion of
thiamine (median, minimum–maximum) was: normal vol-
unteers 0.31 (0.23–2.45) μmol/24 h; type 1 diabetes 1.36
(0.39–7.65) μmol/24 h; and type 2 diabetes 1.04 (0.08–
6.85) μmol/24 h, p<0.001 (Mann–Whitney U test). The
urinary excretion of thiamine was higher in type 1 than in
type 2 diabetic patients (p<0.05) but was not significantly
different in diabetic patients with and without micro-
albuminuria [1.10 (0.08–7.65) vs 1.23 (0.33–6.85) μmol/
24 h, p>0.05]. ClThiamine was increased 24-fold in type 1
diabetic patients and 16-fold in type 2 diabetic patients.
ClThiamine (median, minimum–maximum) was: normal
volunteers 3.7 (2.6–26.2) ml/min; type 1 diabetes 86.5
(12.8–228.4) ml/min; and type 2 diabetes 59.8 (1.4–256.6)
Table 1 Characteristics of normal control volunteers and diabetic patients recruited for this study
Participant
type
n Sex
M/F
Age
(years)
Duration
of diabetes
(years)
BMI
(kg/m2)
GFR
(ml/min)
Fasting plasma
glucose (mmol/l)
HbA1c
(%)
Systolic BP
(mmHg)
Diastolic
BP (mmHg)
ACE inhibitor/
ARB therapy
Control volunteers 20 10/10 53±10 – 27±4 89±18 5.6±0.8 5.0±0.2 ND ND –
Type 1 diabetes 26 10/16 48±15 22.1±13.3 28±5 93±28 9.2±1.7* 8.7±1.2* 131±21 73±11 9
Type 2 diabetes 48 29/19 62±12 13.0±8.9** 31±6 92±30 9.1±2.2* 8.6±1.8* 141±22 77±9 33
Data are mean±SD.
ND Not determined
*p<0.001 with regard to normal volunteers
**p<0.01 with regard to type 1 diabetes (Mann–Whitney U test)
2166 Diabetologia (2007) 50:2164–2170
ml/min, p<0.001 (Mann–Whitney U test). There was no
significant difference in ClThiamine between diabetic patients
with and without microalbuminuria (72.9 [1.4–355.7] vs
66.3 [5.8–245.3] ml/min). FEThiamine was increased 25-fold
in type 1 diabetic patients and 15-fold in type 2 diabetic
patients. FEThiamine (median, minimum–maximum) was:
normal volunteers 2.8% (1.4–17.2%); type 1 diabetes
71.2% (7.6–165.9%); and type 2 diabetes 41.6% (1.1–
228.9%), p<0.001 (Mann–Whitney U test). There was no
significant difference in FEThiamine between diabetic
patients with and without microalbuminuria (57.7% [8.0–
228.9%] vs 43.4% [1.1–165.9%]). Plasma thiamine con-
centration correlated negatively with ClThiamine (r=−0.531,
p<0.001; Spearman) and FEThiamine (r=−0.616, p<0.001;
Spearman) (Fig. 1b,c). There was no significant difference
in these thiamine-related variables between diabetic patients
with and without ACE or ARB therapy.
Thiamine deficiency is assessed conventionally by assay
of TK activity of erythrocytes [12]. Erythrocyte activity of
TK was not changed significantly in diabetic patients, with
regard to normal volunteers. TK activity was: normal
volunteers 1.09±0.06 mU/mg Hb; type 1 diabetes 1.18±
0.25 mU/mg Hb; and type 2 diabetes 1.01±0.17 mU/mg
Hb. Erythrocyte activity of TK was not significantly
different in diabetic patients with and without micro-
albuminuria (1.03±0.24 vs 1.08±0.21 mU/mg Hb), al-
though it correlated negatively with urinary albumin
excretion (r=−0.232, p<0.05; Spearman). All patients were
not thiamine deficient by the definition of the ‘thiamine
effect’; they had a thiamine effect of <15%. The concen-
tration of thiamine in erythrocytes was not changed
significantly in type 1 and type 2 diabetic patients, with
respect to normal volunteers. The concentration of thiamine
in erythrocytes (mean±SD) was: normal volunteers 0.318±
0.028 pmol/mg Hb; type 1 diabetes 0.345±0.025 pmol/mg
Hb; and type 2 diabetes 0.328±0.137 pmol/mg Hb.
Masking of the clinical thiamine deficiency in erythrocytes
by increased levels of thiamine transporter proteins We
sought evidence to understand how erythrocytes of diabetic
patients maintained a normal concentration of thiamine
whilst the plasma concentration of thiamine was severely
decreased. The transport of thiamine and TMP from plasma
to the interior of erythrocytes is mediated by the trans-
porters THTR-1 and RFC-1, respectively (Fig. 2a). Western
blotting of erythrocyte membrane proteins from diabetic
patients showed increased contents of these transporters
compared with membrane-associated housekeeping protein
β-actin (Fig. 2b). Thiamine transporter: β-actin blot
intensity ratios (median, minimum–maximum) were: nor-
mal volunteers (n=10), THTR-1 0.69 (0.12–1.43) and
RFC-1 0.042 (0.012–0.093); type 1 diabetes (n=12),
THTR-1 1.06 (0.64–2.02) (+54%, p<0.05) and RFC-1
0.146 (0.021–0.902) (+248%, p<0.01); and type 2 diabetes
(n=12), THTR-1 1.20 (0.62–2.39) (+74%, p<0.01) and
RFC-1 0.206 (0.038–1.382) (+390%, p<0.001) (Mann–
Whitney U tests).
Low plasma thiamine concentration and markers of
metabolic control and vascular dysfunction We screened
markers of metabolic control and vascular dysfunction in
diabetes for linkage to the low plasma thiamine concentra-
tion in diabetes. The only significant correlations were of
plasma thiamine concentration with plasma sVCAM-1 (r=
−0.246, p<0.05; Spearman) (Fig. 3a) and urinary excretion
of thiamine with plasma sVCAM-1 (r=−0.311, p<0.01)
(Fig. 3b).
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Fig. 1 Thiamine status of diabetic patients and link to sVCAM-1. a
Frequency ribbon graph of plasma thiamine concentration. b Inverse
relationship between plasma thiamine concentration and thiamine
clearance. Nonlinear regression equation: Thiamine½ Plasma ¼ 47:7
Cl 0:274
Thiamine
; p<0:001. c Inverse relationship between plasma thia-
mine concentration and FEThiamine. Nonlinear regression equation:
Thiamine½ Plasma ¼ 74:0 FE 0:448Thiamine ; p<0:001
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Discussion
In this study we found clinical diabetes was associated with
a marked deficiency of thiamine in blood plasma linked to
increased ClThiamine and FEThiamine. The low plasma
thiamine concentration in diabetes was linked inversely to
plasma sVCAM-1.
The strengths of this study were the use of a validated
assay for thiamine and phosphorylated metabolites, a
comprehensive assessment of thiamine-related variables
(including thiamine transporter content of erythrocyte
membranes, urinary excretion, ClThiamine and FEThiamine)
and investigation of the association of thiamine-related
variables with markers of metabolic and vascular dysfunc-
tion. The decreased plasma thiamine concentration in
clinical diabetes was probably not due to a deficiency of
dietary input of thiamine. The urinary excretion of thiamine
of diabetic patients and normal healthy volunteers was
within the normal range (>0.20 μmol/24 h) [19], except for
one type 2 diabetic patient with a urinary thiamine
excretion of 0.08 μmol/24 h. Urinary excretion of thiamine
accounts for a minor part of normal thiamine turnover:
pyrimidine and thiazole degradation products of thiamine
are also excreted in the urine and account for the major
component of thiamine turnover [20]. Rather, low plasma
thiamine concentration was linked to a profound increase in
ClThiamine and FEThiamine. The molecular mass of thiamine
is <500 Da and hence it is filtered from plasma in renal
glomeruli [10]. Increased ClThiamine is probably due to
decreased re-uptake of thiamine in renal proximal tubules.
Thiamine clearance was dysfunctional in diabetic patients
with normal GFR, as assessed by creatinine clearance. This
study suggests renal mishandling of thiamine in diabetic
patients is an early marker of renal dysfunction in diabetes
and, linked to the locus of renal thiamine re-uptake,
particularly relates to proximal tubule dysfunction.
Re-uptake of thiamine occurs in the proximal tubules by
thiamine transporters THTR-1 and THTR-2 via a sodium-
independent, proton antiport mechanism with regulation by
Ca2+/calmodulin [21]. The expression of the genes encod-
ing THTR-1 and THTR-2 (and also RFC-1) transporters are
regulated via SP1 promoter elements [22–24]. SP1 signal-
ling in the tubular epithelium is impaired in hyperglycaemia
associated with diabetes by increased O-glycosylation of
the SP1 via enhanced hexosamine pathway activity [25].
Re-uptake of thiamine by the tubular epithelium in
experimental diabetes [26] and clinical diabetes (this work)
may be impaired by hexosamine pathway-linked decreased
expression of the genes encoding THTR-1 and THTR-2,
inhibition of these thiamine transporters by dicarbonyl
glycation [27] and acidification of the tubular lumen [28].
This deserves further investigation.
A weakness of the study was the finding of no strong
link to a recognised clinical endpoint such as incipient
nephropathy judged by microalbuminuria, although there
was a weak negative correlation of erythrocyte TK activity
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Fig. 3 Correlation of sVCAM-1 with plasma thiamine concentration
(a) and urinary thiamine excretion (b). Solid horizontal line, reference
mean of sVCAM-1 of normal volunteers; broken horizontal line,
upper limit of sVCAM-1 of normal volunteers
Fig. 2 a Schematic diagram of thiamine membrane transport and
metabolism in erythrocytes. b Representative Western blot of THTR-1,
RFC-1 and housekeeping protein β-actin of erythrocyte membranes.
Lanes 1–3, normal volunteers; lanes 4–6, type 1 diabetic patients; and
lanes 7–9, type 2 diabetic patients. T, Thiamine
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with urinary albumin excretion. It is becoming increasingly
evident, however, that urinary albumin excretion may not
be a reliable marker of early stage decline in renal function
in diabetes [29]. Future studies would be probably better
addressed to investigation of the link between changes in
thiamine homeostasis and early decline in GFR assessed by
cystatin C measurement [30].
Decreased plasma thiamine concentration has been
reported in diabetic patients previously in studies with small
patient numbers [31, 32] but ClThiamine and FEThiamine,
thiamine and TMP transporter content of erythrocyte
membranes and plasma sVCAM-1 were not evaluated and
hence links to these variables were not disclosed. Thiamine
deficiency is conventionally assessed by measuring the
percentage unsaturation of erythrocyte TK with TPP cofactor
[12]. Herein we found, however, that plasma deficiency of
thiamine in diabetes was masked in erythrocytes by
increased levels of THTR-1 and RFC-1 transporter protein.
As erythrocytes lack protein synthetic capability, increased
protein levels of these transporters was produced by
increased expression of the genes encoding THTR-1 and
RFC-1 in the erythrocyte precursors, reticulocytes and
erythroblasts. Indeed, increased levels of THTR-1 and
RFC-1 transporter proteins were also found in MNLs in
these diabetic patients (data not shown). Increased thiamine
transporter gene expression and protein level is a response to
thiamine deficiency [21, 33] and is consistent with the low
plasma thiamine concentration found in diabetic patients
herein. This explains why a low plasma thiamine concentra-
tion in clinical diabetes has hitherto gone unrecognised. This
study indicates that the measurement of the ‘thiamine effect’
based on erythrocyte TK activities is an inadequate
assessment of clinical thiamine status as it can be masked
by changes in thiamine transporter protein levels.
Low plasma thiamine concentration in diabetes may be
of limited significance if tissues can upregulate the gene
expression and protein levels of thiamine transporters and
maintain normal TK activity. Although this occurs in the
normoglycaemic state [21, 33], our recent studies of
experimental diabetes indicated it does not occur in renal
glomeruli in the diabetic state [26] where enhanced hexos-
amine signalling may block increased expression of the
genes encoding THTR-1, THTR-2 and RFC-1 and their
protein levels. In diabetic glomeruli, TK activity and level
of TK protein was decreased 60% [26], and similar
impairment of thiamine uptake and metabolism may occur
in the diabetic retina and peripheral nerve [34, 35]. Indeed,
RFC-1 has impaired gene expression and protein levels in
the diabetic retina [35].
Decreased availability of thiamine in vascular cells in
diabetes exacerbates metabolic dysfunction in hyperglycae-
mia. Increased plasma sVCAM-1 is a marker of endothelial
dysfunction [36] and increased risk of atherosclerosis [37].
sVCAM-1 was increased in diabetic patients with normal
renal function [38] and was linked to microvascular and
macrovascular complications in diabetes [39–41], although
the link to glycaemic control is less certain [39, 42, 43].
Low plasma thiamine concentration may be a confounding
factor linked to increased sVCAM-1 in diabetes.
This study indicates that type 1 and type 2 diabetic
patients in the UK exhibit low plasma thiamine concentra-
tion. The conventional indicator of thiamine sufficiency,
erythrocyte TK activity, is masked in clinical diabetes by
increased protein levels of thiamine and TMP transporters,
THTR-1 and RFC-1. The deficiency of thiamine in clinical
diabetes may increase the fragility of vascular cells to the
adverse effects of hyperglycaemia and thereby increase the
risk of developing microvascular complications. Correction
of the low plasma thiamine concentration with thiamine
supplements may decrease the risk of microvascular com-
plications in diabetes.
Important areas for future study are: (1) confirmation of
low plasma thiamine concentrations in diabetic populations
of other countries independent of local dietary and culinary
practice; (2) the evaluation of thiamine and thiamine
derivatives to correct low plasma thiamine concentration
in diabetes, reverse vascular dysfunction and prevent vas-
cular complications; and (3) investigation of the mechanism
of increased ClThiamine in diabetes. These studies are either
ongoing or in preparation.
Acknowledgements This study was funded by a project grant from
Diabetes UK (RD/04/2812).
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
References
1. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD (2000)
ABC of arterial and venous disease: vascular complications of
diabetes. BMJ 320:1062–1066
2. American Diabetes Association (2007) Standards of medical care
in diabetes—2007. Diabetes Care 30:S4–S41
3. Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk
factors for vascular disease among adults with previously diag-
nosed diabetes. JAMA 291:335–342
4. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG
(2006) Prevalence and risk factors for microalbuminuria in a
referred cohort of type II diabetic patients: a global perspective.
Kidney Internat 69:2057–2063
5. The Diabetes Control and Complications Trial Research Group
(1993) The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. New Engl J Med 327:977–986
6. Stratton IM, Adler AI, Neil HAW et al (2002) Association of
glycaemic with macrovascular and microvascular complications
of type 2 diabetes (UKPDS 35): prospective observational study.
BMJ 321:405–412
Diabetologia (2007) 50:2164–2170 2169
7. Rogus JJ, Warram JH, Krolewski AS (2002) Genetic studies of
late diabetic complications: the overlooked importance of diabetes
duration before complication onset. Diabetes 51:1655–1662
8. Placha G, Poznik GD, Dunn J et al (2006) A genome-wide
linkage scan for genes controlling variation in renal function
estimated by serum cystatin C levels in extended families with
type 2 diabetes. Diabetes 55:3358–3365
9. Costacou T, Chang Y, Ferrell RE, Orchard TJ (2006) Identifying
genetic susceptibilities to diabetes-related complications among
individuals at low risk of complications: an application of tree-
structured survival analysis. Am J Epidemiol 164:862–872
10. Thornalley PJ (2005) The potential role of thiamine (vitamin B1)
in diabetic complications. Curr Diabetes Res 1:287–298
11. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley
PJ (2004) High dose thiamine therapy counters dyslipidaemia in
streptozotocin-induced diabetic rats. Diabetologia 47:2235–2246
12. Brady JA, Rock CL, Horneffer MR (1995) Thiamin status,
diuretic medications, and the management of congestive heart
failure. J Am Diet Assoc 95:541–544
13. Sander S, Hahn A, Stein J, Rehner G (1991) Comparative studies
on the high performance liquid chromatographic determination of
thiamine and its phosphate esters with chloroethylamine as an
internal standard using precolumn and postcolumn derivatization
procedures. J Chromatogr 558:115–124
14. Dawson RMC, Elliott DC, Elliott WH, Jones KM (1989) Data for
biochemical research, 3rd edn. Oxford University Press, Oxford
15. Cull CA, Manley SE, Stratton IM et al (1997) Approach to
maintaining comparability of biochemical data during long-term
clinical trials. Clin Chem 43:1913–1918
16. Dutta B, Huang W, Molero M et al (1999) Cloning of the human
thiamine transporter, a member of the folate transporter family.
J Biol Chem 274:31925–31929
17. Zhao R, Gao F, Goldman ID (2002) Reduced folate carrier
transports thiamine monophosphate: an alternative route for
thiamine delivery into mammalian cells. Am J Physiol Cell
Physiol 282:C1512–C1517
18. Churchward M, Butt RH, Lang J, Hsu K, Coorssen J (2005)
Enhanced detergent extraction for analysis of membrane pro-
teomes by two-dimensional gel electrophoresis. Proteome Sci 3:5
19. Finglas PM (1993) Thiamin. Internat J Vitam Nutr Res 63:270–
274
20. Ziporin ZZ, Nunes WT, Powell RC, Waring PP, Sauberlich HE
(1965) Thiamine requirement in the adult human as measured
by urinary excretion of thiamine metabolites. J Nutr 85:297–304
21. Ashokkumar B, Vaziri ND, Said HM (2006) Thiamin uptake by the
human-derived renal epithelial (HEK-293) cells: cellular and
molecular mechanisms. Am J Physiol Renal Physiol 291:F796–F805
22. Reidling JC, Said HM (2003) In vitro and in vivo characterization
of the minimal promoter region of the human thiamin transporter
SLC19A2. Am J Physiol Cell Physiol 285:C633–C641
23. Nabokina SM, Said HM (2004) Characterization of the 5′-
regulatory region of the human thiamin transporter SLC19A3: in
vitro and in vivo studies. Am J Physiol Gastrointest Liver Physiol
287:G822–G829
24. Tolner B, Singh A, Esaki T, Roy K, Sirotnak FM (1999)
Transcription of the mouse RFC-1 gene encoding a folate
transporter. Multiplicity and properties of promoters with mini-
mum requirements for their basal activity. Gene 231:163–172
25. Schleicher ED, Weigert C (2000) Role of the hexosamine biosyn-
thetic pathway in diabetic nephropathy. Kidney Int 58:S13–S18
26. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley
PJ (2003) Prevention of incipient diabetic nephropathy by high
dose thiamine and Benfotiamine. Diabetes 52:2110–2120
27. Verri A, Laforenza U, Gastaldi G, Tosco M, Rindi G (2002)
Molecular characteristics of small intestinal and renal brush border
thiamin transporters in rats. Biochim Biophys Acta 1558:187–197
28. Nascimento-Gomes G, Zaladek Gil F, Mello-Aires M (1997)
Alterations of the renal handling of H+ in diabetic rats. Kidney
Blood Press Res 20:251–257
29. Perkins BA, Ficociello LH, Ostrander BE et al (2007) Micro-
albuminuria and the risk for early progressive renal function
decline in type 1 diabetes. J Am Soc Nephrol 18:1353–1361
30. MacIsaac RJ, Tsalamandris C, Thomas MC et al (2007) The
accuracy of cystatin C and commonly used creatinine-based
methods for detecting moderate and mild chronic kidney disease
in diabetes. Diabetic Med 24:443–448
31. Saito N, Kimura M, Kuchiba A, Itokawa Y (1987) Blood thiamine
levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol
33:421–430
32. Valerio G, Franzese A, Poggi V, Patrini C, Laforenza U, Tenore A
(1999) Lipophilic thiamine treatment in longstanding insulin-
dependent diabetes mellitus. Acta Diabetol 36:73–76
33. Laforenza U, Patrini C, Alvisi C, Faelli A, Licandro A, Rindi G
(1997) Thiamine uptake in human intestinal biopsy specimens,
including observations from a patient with acute thiamine
deficiency. Am J Clin Nutr 66:320–326
34. Gorson KC, Ropper AH (2006) Additional causes for distal
sensory polyneuropathy in diabetic patients. J Neurol Neurosurg
Psychiatry 77:354–358
35. Naggar H, Ola MS, Moore P et al (2002) Downregulation of
reduced-folate transporter by glucose in cultured RPE cells and
in RPE of diabetic mice. Invest Ophthalmol Vis Sci 43:556–563
36. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ,
Parving H-H (2002) Increased urinary albumin excretion, endo-
thelial dysfunction, and chronic low-grade inflammation in type 2
diabetes. Diabetes 51:1157–1165
37. Jager A, van Hinsbergh VW, Kostense PJ et al (2000) Increased
levels of soluble vascular cell adhesion molecule 1 are associated
with risk of cardiovascular mortality in type 2 diabetes: the Hoorn
study. Diabetes 49:485–491
38. Lim SC, Caballero AE, Smakowski P, LoGerfo FW, Horton ES,
Veves A (1999) Soluble intercellular adhesion molecule, vascular
cell adhesion molecule, and impaired microvascular reactivity are
early markers of vasculopathy in type 2 diabetic individuals
without microalbuminuria. Diabetes Care 22:1865–1870
39. Fasching P, Veitl M, Rohac M et al (1996) Elevated concen-
trations of circulating adhesion molecules and their association
with microvascular complications in insulin-dependent diabetes
mellitus. J Clin Endocrinol Metab 81:4313–4317
40. Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S (1998)
Relationship between circulating vascular cell adhesion molecule-1
and microvascular complications in type 2 diabetes mellitus. Diabet
Med 15:661–667
41. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, Stehouwer
CDA, Ebeling P, Fuller JH (2006) Soluble vascular cell adhesion
molecule-1 and soluble E-selectin are associated with micro- and
macrovascular complications in type 1 diabetic patients. J Diabetes
Complications 20:188–195
42. Schaumberg DA, Glynn RJ, Jenkins AJ et al (2005) Effect of
intensive glycemic control on levels of markers of inflammation in
type 1 diabetes mellitus in the diabetes control and complications
trial. Circulation 111:2446–2453
43. Matsumoto K, Nakamura H, Ueki Y, Tominga T, Miyake S (2001)
Correction of hyperglycaemia reduces insulin resistance and
serum soluble E-selectin levels in patients with type 2 diabetes
mellitus. Diabet Med 18:224–228
2170 Diabetologia (2007) 50:2164–2170
